Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

<p>The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in more than 20 years LX9211 has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP THE WOODLANDS, Texas, Nov. […]</p>
<p>The post <a href="https://forextv.com/top-news/lexicon-enrolls-first-patient-in-phase-2b-progress-study-of-lx9211-in-diabetic-peripheral-neuropathic-pain-dpnp/">Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>